|
Valoración de DCF de Emergent Biosolutions Inc. (EBS)
US | Healthcare | Drug Manufacturers - Specialty & Generic | NYSE
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Emergent BioSolutions Inc. (EBS) Bundle
¡Explore el futuro financiero de Emergent Biosolutions Inc. (EBS) con nuestra calculadora DCF fácil de usar! Ingrese sus proyecciones para el crecimiento, los márgenes y los gastos para calcular el valor intrínseco de Emergent Biosolutions Inc. (EBS) y mejorar su estrategia de inversión.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,106.0 | 1,555.4 | 1,792.7 | 1,120.9 | 1,049.3 | 1,080.9 | 1,113.4 | 1,146.8 | 1,181.3 | 1,216.8 |
| Revenue Growth, % | 0 | 40.63 | 15.26 | -37.47 | -6.39 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| EBITDA | 227.3 | 549.0 | 458.2 | -32.9 | -505.3 | 65.5 | 67.5 | 69.5 | 71.6 | 73.8 |
| EBITDA, % | 20.55 | 35.3 | 25.56 | -2.94 | -48.16 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 |
| Depreciation | 110.9 | 114.4 | 126.3 | 148.9 | 125.1 | 107.3 | 110.5 | 113.8 | 117.3 | 120.8 |
| Depreciation, % | 10.03 | 7.36 | 7.05 | 13.28 | 11.92 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
| EBIT | 116.4 | 434.6 | 331.9 | -181.8 | -630.4 | -41.8 | -43.0 | -44.3 | -45.6 | -47.0 |
| EBIT, % | 10.52 | 27.94 | 18.51 | -16.22 | -60.08 | -3.86 | -3.86 | -3.86 | -3.86 | -3.86 |
| Total Cash | 167.8 | 621.3 | 576.1 | 642.6 | 111.7 | 335.6 | 345.6 | 356.0 | 366.7 | 377.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 270.7 | 230.9 | 278.9 | 159.2 | 191.0 | 188.7 | 194.4 | 200.2 | 206.2 | 212.4 |
| Account Receivables, % | 24.48 | 14.85 | 15.56 | 14.2 | 18.2 | 17.46 | 17.46 | 17.46 | 17.46 | 17.46 |
| Inventories | 222.5 | 307.0 | 350.8 | 351.8 | 328.9 | 264.1 | 272.0 | 280.2 | 288.6 | 297.3 |
| Inventories, % | 20.12 | 19.74 | 19.57 | 31.39 | 31.34 | 24.43 | 24.43 | 24.43 | 24.43 | 24.43 |
| Accounts Payable | 94.8 | 136.1 | 128.9 | 103.5 | 112.2 | 96.1 | 99.0 | 101.9 | 105.0 | 108.1 |
| Accounts Payable, % | 8.57 | 8.75 | 7.19 | 9.23 | 10.69 | 8.89 | 8.89 | 8.89 | 8.89 | 8.89 |
| Capital Expenditure | -86.9 | -141.0 | -225.0 | -115.8 | -51.6 | -96.7 | -99.6 | -102.6 | -105.7 | -108.8 |
| Capital Expenditure, % | -7.86 | -9.07 | -12.55 | -10.33 | -4.92 | -8.94 | -8.94 | -8.94 | -8.94 | -8.94 |
| Tax Rate, % | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 | -4.01 |
| EBITAT | 82.0 | 326.4 | 231.7 | -183.5 | -655.7 | -34.7 | -35.7 | -36.8 | -37.9 | -39.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -292.4 | 296.4 | 34.0 | -57.1 | -582.4 | 27.0 | -35.5 | -36.6 | -37.7 | -38.8 |
| WACC, % | 8.74 | 9.06 | 8.7 | 10.77 | 10.77 | 9.61 | 9.61 | 9.61 | 9.61 | 9.61 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -83.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -40 | |||||||||
| Terminal Value | -521 | |||||||||
| Present Terminal Value | -329 | |||||||||
| Enterprise Value | -412 | |||||||||
| Net Debt | 749 | |||||||||
| Equity Value | -1,161 | |||||||||
| Diluted Shares Outstanding, MM | 51 | |||||||||
| Equity Value Per Share | -22.67 |
What You Will Get
- Real Emergent BioSolutions Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Emergent BioSolutions' fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Data: Emergent BioSolutions Inc.’s (EBS) historical financial statements and detailed forecasts.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Analysis: Watch Emergent BioSolutions Inc.’s (EBS) intrinsic value update instantly.
- Intuitive Visuals: Dashboard charts illustrate valuation outcomes and essential metrics.
- Designed for Precision: A reliable tool for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-formatted Excel file featuring Emergent BioSolutions Inc. (EBS) financial data.
- Customize: Modify forecasts such as revenue growth, EBITDA %, and WACC to suit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make changes.
- Test Scenarios: Develop various projections and instantly compare different outcomes.
- Make Decisions: Leverage the valuation findings to inform your investment strategy.
Why Choose This Calculator for Emergent BioSolutions Inc. (EBS)?
- User-Friendly Interface: Perfectly crafted for both novice users and seasoned professionals.
- Customizable Inputs: Effortlessly adjust parameters to suit your specific analysis needs.
- Real-Time Feedback: Monitor immediate changes to Emergent BioSolutions' valuation as you tweak inputs.
- Preloaded Financial Data: Comes with Emergent BioSolutions' actual financial figures for swift evaluation.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive valuation models for analyzing portfolios in the biotech sector.
- Corporate Finance Teams: Assess valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for Emergent BioSolutions Inc. (EBS) to clients.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech firms like Emergent BioSolutions Inc. (EBS) are valued in the marketplace.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Emergent BioSolutions Inc. (EBS).
- Real-World Data: Emergent BioSolutions’ historical and projected financials preloaded for thorough analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns for enhanced insights into the company's performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage specific to Emergent BioSolutions Inc. (EBS).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable insights.